Please assess the completion status of the following clinical trial:

Trial Title: UNITY 2: A Study of an Investigational Treatment Regimen of DCV+ASV+BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) With or Without RBV for 12 Weeks for the Treatment of Chronic Hepatitis C Virus(HCV)Genotype 1 Infection in Subjects With Compensated Cirrhosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com~Inclusion Criteria:~* Subjects chronically infected with HCV genotype 1~* Subjects with compensated cirrhosis~* HCV RNA ≥ 10,000 IU/mL at screening~* Treatment-naïve subjects with no previous exposure to an interferon formulation (ie, IFNα, pegIFNα), Ribavirin (RBV), or HCV Direct Acting Antivirals (DAA) (protease, polymerase inhibitor, etc.)~* Treatment-experienced subjects are eligible including exposure to anti-HCV agents of a mechanistic class other than those contained in the Daclatasvir (DCV) / Asunaprevir (ASV) /BMS-791325 triple regimen is permitted. Examples of permitted agents include, but are not limited to nucleoside/nucleotide inhibitors of nonstructural protein 5B (NS5B) polymerase, inhibitors of cyclophilin, or inhibitors of microRNA.~Exclusion Criteria:~* Subjects without cirrhosis~* Liver or any other organ transplant~* Current or known history of cancer within 5 years prior to screening~* Documented or suspected hepatocellular carcinoma(HCC)~* Evidence of decompensated liver disease including, but not limited to, radiologic criteria, a history or presence of ascites, bleeding varices, or hepatic encephalopathy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A1: DCV/ASV/BMS-791325+Placebo matching RBV (naive) (Type: EXPERIMENTAL): Triple fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg, BMS-791325 75 mg) tablet orally twice a day for 12 weeks~Placebo matching Ribavirin 0mg tablet orally twice a day for 12 weeks
- A2: DCV/ASV/BMS-791325 + RBV (naive) (Type: EXPERIMENTAL): Triple fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg, BMS-791325 75 mg) tablet orally twice a day for 12 weeks~Ribavirin 200mg tablet orally twice a day for 12 weeks
- A3: DCV/ASV/BMS-791325+Placebo matching RBV (experienced) (Type: EXPERIMENTAL): Triple fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg, BMS-791325 75 mg) tablet orally twice a day for 12 weeks~Placebo matching Ribavirin 0 mg tablet orally twice a day for 12 weeks
- A4: DCV/ASV/BMS-791325 + RBV (experienced) (Type: EXPERIMENTAL): Triple fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg, BMS-791325 75 mg) tablet orally twice a day for 12 weeks~Ribavirin 200 mg tablet orally twice a day for 12 weeks, Weight based dosing: If \< 75 kg, 1000 mg per day (two 200 mg tablets in AM and three 200 mg tablets in PM); if ≥ 75 kg, 1200 mg per day (three 200 mg tablets in AM and three 200 mg tablets in PM), AM=in the morning, PM=in the evening

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete